Table Info

Table 1.

The results of replication MR analysis

Outcome	Exposure	SNP	IVW			MR-Egger			WM
Outcome	Exposure	SNP	OR	95%CI	p	OR	95%CI	p	OR	95%CI	p
GCST90038685	AKT	21	1.006	(0.943, 1.072)	0.866	1.051	(0.906, 1.221)	0.519	1.027	(0.947, 1.114)	0.524
	ATF6	34	0.831	(0.682, 1.014)	0.068	0.54	(0.294, 0.992)	0.057	1.048	(0.973, 1.129)	0.213
	ATG7	18	1.044	(0.953, 1.144)	0.353	0.923	(0.762, 1.118)	0.425	1.037	(0.925, 1.164)	0.533
	BECN1	26	1.033	(0.966, 1.105)	0.346	0.972	(0.825, 1.145)	0.737	1.051	(0.958, 1.152)	0.29
	EIF4A3	13	1.059	(0.996, 1.126)	0.068	1.024	(0.911, 1.150)	0.705	1.031	(0.955, 1.112)	0.439
	EIF4B	26	1.013	(0.958, 1.071)	0.65	1.082	(0.956, 1.225)	0.223	1.000	(0.919, 1.089)	0.994
	EIF4E2	24	0.994	(0.943, 1.047)	0.809	1.031	(0.929, 1.145)	0.570	1.012	(0.937, 1.094)	0.762
	EIF4EBP2	28	0.993	(0.918, 1.074)	0.861	1.064	(0.863, 1.312)	0.566	0.959	(0.866, 1.064)	0.433
	EIF4G3	21	1.009	(0.916, 1.112)	0.852	0.953	(0.755, 1.204)	0.694	0.982	(0.873, 1.105)	0.768
	HIF1A	24	0.999	(0.933, 1.070)	0.969	0.963	(0.833, 1.112)	0.612	1.028	(0.933, 1.132)	0.579
	ULK3	19	1.006	(0.917, 1.103)	0.899	1.052	(0.820, 1.350)	0.697	1.001	(0.905, 1.1.7)	0.986
	LST1	24	0.829	(0.614, 1.120)	0.222	0.870	(0.405, 1.868)	0.724	0.976	(0.895, 1.064)	0.585
	PKC-A	20	0.989	(0.926, 1.057)	0.750	0.988	(0.853, 1.143)	0.870	0.984	(0.898, 1.079)	0.735
	RPS6KA	28	1.048	(0.956, 1.150)	0.315	0.930	(0.797, 1.085)	0.369	1.011	(0.941, 1.087)	0.763

CI: confidence interval; IVW: inverse variance weighted; MR: Mendelian randomization; OR: odds ratio; SNP: single nucleotide polymorphism; WM: weighted median

Supplementary materials

The supplementary tables for this article are available at: https://www.explorationpub.com/uploads/Article/file/1001264_sup_1.pdf.

Declarations

Author contributions

ZY: Conceptualization, Validation, Writing—original draft. JL: Data curation, Formal analysis, Visualization, Writing—original draft. RZ: Conceptualization, Writing—original draft. HZ: Data curation, Formal analysis, Visualization. SZ: Validation, Supervision, Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The study utilized summary statistics from publicly available datasets, the IEU database. As such, this research did not involve direct contact with human participants or the collection of new personal data, and therefore, the ethical approval was not required.

Consent to participate

This study analyzed secondary data from the IEU database, therefore, the consent to participate is not required.

Consent to publication

Not applicable.

Availability of data and materials

Publicly available datasets were analyzed in this study. All of our data comes from the IEU database. This data can be found here: IEU OpenGWAS project (mrcieu.ac.uk). The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Funding

This work was supported by the National Natural Science Foundation of China [No. 82001740]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205–19. [DOI] [PubMed]

Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2017;31:3–18. [DOI] [PubMed] [PMC]

MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 2000;43:30–7. [DOI] [PubMed]

Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023–38. [DOI] [PubMed]

Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506:376–81. [DOI] [PubMed] [PMC]

Li P, Liu D, Liu Y, Song S, Wang Q, Chang Y, et al. BAFF/BAFF-R involved in antibodies production of rats with collagen-induced arthritis via PI3K-Akt-mTOR signaling and the regulation of paeoniflorin. J Ethnopharmacol. 2012;141:290–300. [DOI] [PubMed]

Wu MC, Kraft P, Epstein MP, Taylor DM, Chanock SJ, Hunter DJ, et al. Powerful SNP-set analysis for case-control genome-wide association studies. Am J Hum Genet. 2010;86:929–42. [DOI] [PubMed] [PMC]

Li C, Yang W, Wei Q, Shang H. Causal Association of Leukocytes Count and Amyotrophic Lateral Sclerosis: a Mendelian Randomization Study. Mol Neurobiol. 2020;57:4622–7. [DOI] [PubMed]

Lawlor DA, Harbord RM, Sterne JAC, Timpson N, Smith GD. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27:1133–63. [DOI] [PubMed]

10.

Burgess S, Daniel RM, Butterworth AS, Thompson SG; Consortium E. Network Mendelian randomization: using genetic variants as instrumental variables to investigate mediation in causal pathways. Int J Epidemiol. 2015;44:484–95. [DOI] [PubMed] [PMC]

11.

Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic atlas of the human plasma proteome. Nature. 2018;558:73–9. [DOI] [PubMed] [PMC]

12.

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24. [DOI] [PubMed]

13.

Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37:658–65. [DOI] [PubMed] [PMC]

14.

Bowden J, Smith GD, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44:512–25. [DOI] [PubMed] [PMC]

15.

Bowden J, Smith GD, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016;40:304–14. [DOI] [PubMed] [PMC]

16.

Ishigaki K, Sakaue S, Terao C, Luo Y, Sonehara K, Yamaguchi K, et al. Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis. Nat Genet. 2022;54:1640–51. [DOI] [PubMed] [PMC]

17.

Raha S, Yumnam S, Hong GE, Lee HJ, Saralamma VVG, Park H, et al. Naringin induces autophagy-mediated growth inhibition by downregulating the PI3K/Akt/mTOR cascade via activation of MAPK pathways in AGS cancer cells. Int J Oncol. 2015;47:1061–9. [DOI] [PubMed]

18.

Chen J, Crawford R, Xiao Y. Vertical inhibition of the PI3K/Akt/mTOR pathway for the treatment of osteoarthritis. J Cell Biochem. 2013;114:245–9. [DOI] [PubMed]

19.

Zhang Z, Yao L, Yang J, Wang Z, Du G. PI3K/Akt and HIF-1 signaling pathway in hypoxiaischemia (Review). Mol Med Rep. 2018;18:3547–54. [DOI] [PubMed] [PMC]

20.

Malemud CJ. Intracellular Signaling Pathways in Rheumatoid Arthritis. J Clin Cell Immunol. 2013;4:160. [DOI] [PubMed] [PMC]

21.

Karonitsch T, Kandasamy RK, Kartnig F, Herdy B, Dalwigk K, Niederreiter B, et al. mTOR Senses Environmental Cues to Shape the Fibroblast-like Synoviocyte Response to Inflammation. Cell Rep. 2018;23:2157–67. [DOI] [PubMed] [PMC]

22.

Bishop EL, Gudgeon N, Fulton-Ward T, Stavrou V, Roberts J, Boufersaoui A, et al. TNF-alpha signals through ITK-Akt-mTOR to drive CD4(+) T cell metabolic reprogramming, which is dysregulated in rheumatoid arthritis. Sci Signal. 2024;17:5–8. [DOI] [PubMed]

23.

Fenton TR, Gout IT. Functions and regulation of the 70kDa ribosomal S6 kinases. Int J Biochem Cell Biol. 2011;43:47–59. [DOI] [PubMed]

24.

Kühnle N, Dederer V, Lemberg MK. Intramembrane proteolysis at a glance: from signalling to protein degradation. J Cell Sci. 2019;132:jcs217745. [DOI] [PubMed]

25.

Meusser B, Hirsch C, Jarosch E, Sommer T. ERAD: the long road to destruction. Nat Cell Biol. 2005;7:766–72. [DOI] [PubMed]

26.

Ahner A, Brodsky JL. Checkpoints in ER-associated degradation: excuse me, which way to the proteasome? Trends Cell Biol. 2004;14:474–8. [DOI] [PubMed]

27.

McCracken AA, Brodsky JL. Evolving questions and paradigm shifts in endoplasmic-reticulum-associated degradation (ERAD). Bioessays. 2003;25:868–77. [DOI] [PubMed]

28.

Hampton RY. ER-associated degradation in protein quality control and cellular regulation. Curr Opin Cell Biol. 2002;14:476–82. [DOI] [PubMed]

29.

Levine B, Kroemer G. Biological Functions of Autophagy Genes: A Disease Perspective. Cell. 2019;176:11–42. [DOI] [PubMed] [PMC]

30.

Itakura E, Kishi C, Inoue K, Mizushima N. Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG. Mol Biol Cell. 2008;19:5360–72. [DOI] [PubMed] [PMC]

31.

Sakellariou D, Frankel LB. EIF4A3: a gatekeeper of autophagy. Autophagy. 2021;17:4504–5. [DOI] [PubMed] [PMC]

32.

Salzman J. Circular RNA Expression: Its Potential Regulation and Function. Trends Genet. 2016;32:309–16. [DOI] [PubMed] [PMC]

33.

Shang Q, Yang Z, Jia R, Ge S. The novel roles of circRNAs in human cancer. Mol Cancer. 2019;18:6. [DOI] [PubMed] [PMC]

34.

Barrett SP, Salzman J. Circular RNAs: analysis, expression and potential functions. Development. 2016;143:1838–47. [DOI] [PubMed] [PMC]

35.

González-Rodríguez P, Cheray M, Keane L, Engskog-Vlachos P, Joseph B. ULK3-dependent activation of GLI1 promotes DNMT3A expression upon autophagy induction. Autophagy. 2022;18:2769–80. [DOI] [PubMed] [PMC]

36.

Fabisik M, Tureckova J, Pavliuchenko N, Kralova J, Balounova J, Vicikova K, et al. Regulation of Inflammatory Response by Transmembrane Adaptor Protein LST1. Front Immunol. 2021;12:618332. [DOI] [PubMed] [PMC]

37.

Liu M, Gu C, Wang Y. Upregulation of the tight junction protein occludin: effects on ventilation-induced lung injury and mechanisms of action. BMC Pulm Med. 2014;14:94. [DOI] [PubMed] [PMC]

38.

Buckley CD, Barone F, Nayar S, Bénézech C, Caamaño J. Stromal cells in chronic inflammation and tertiary lymphoid organ formation. Annu Rev Immunol. 2015;33:715–45. [DOI] [PubMed]

39.

Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010;233:233–55. [DOI] [PubMed] [PMC]

40.

Zhang Q, Liu J, Zhang M, Wei S, Li R, Gao Y, et al. Apoptosis Induction of Fibroblast-Like Synoviocytes Is an Important Molecular-Mechanism for Herbal Medicine along with its Active Components in Treating Rheumatoid Arthritis. Biomolecules. 2019;9:795. [DOI] [PubMed] [PMC]

41.

Ma J, Jing J, Wang J, Yan T, Li Q, Mo Y, et al. A novel function of artesunate on inhibiting migration and invasion of fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Res Ther. 2019;21:153. [DOI] [PubMed] [PMC]

42.

Laragione T, Gulko PS. mTOR regulates the invasive properties of synovial fibroblasts in rheumatoid arthritis. Mol Med. 2010;16:352–8. [DOI] [PubMed] [PMC]

43.

Zhang S, Hu X, H, Su Q, Zhang Cheng T, Wang J, et al. Rapamycin suppresses rheumatoid arthritis fibroblast synovial cell proliferation and induces apoptosis via the AKT/mTORC1 pathway. Rheumatol Autoimmun. 2024;4:156–64. [DOI]

44.

Cejka D, Hayer S, Niederreiter B, Sieghart W, Fuereder T, Zwerina J, et al. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. Arthritis Rheum. 2010;62:2294–302. [DOI] [PubMed]

45.

Zhang F, Cheng T, Zhang S. Mechanistic target of rapamycin (mTOR): a potential new therapeutic target for rheumatoid arthritis. Arthritis Res Ther. 2023;25:187. [DOI] [PubMed] [PMC]

46.

Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol. 2009;29:1411–20. [DOI] [PubMed] [PMC]

47.

Kaneko Y, Tanigawa N, Sato Y, Kobayashi T, Nakamura S, Ito E, et al. Oral administration of N-acetyl cysteine prevents osteoarthritis development and progression in a rat model. Sci Rep. 2019;9:18741. [DOI] [PubMed] [PMC]

48.

Yeh Y, Liang C, Chang C, Hsu C, Li P. Increased risk of knee osteoarthritis in patients using oral N-acetylcysteine: a nationwide cohort study. BMC Musculoskelet Disord. 2020;21:531. [DOI] [PubMed] [PMC]